Pull up a chair at Peptide Friend

Six insomniacs and a sleep peptide

In a 1981 study of six middle-aged people with chronic insomnia, synthetic DSIP was followed by longer sleep, fewer interruptions and slightly more REM sleep, without daytime sedation. The sleep improvement appeared in the second hour. In the first, the researchers described slight arousal.

That awkward first hour earns its place at the table. Delta Sleep-Inducing Peptide has a name that seems to finish the conversation before it starts, yet this little study contains a delay and a response in the opposite direction before the reported benefit. The finding deserves its full sequence of events.

For me, the friendly thing is to leave room for that complication. Peptide Friend began with curiosity about sleep, anxiety and concentration, and became a place to spend longer with findings that resist an easy recommendation. There is plenty to talk about. Start with DSIP’s sleep research and safety data.

Selank and another anxiety drug

The Selank experiment in chronically stressed rats gives the conversation a different turn. The combination of Selank and diazepam reduced anxiety-related behavior more effectively than either intervention alone, moving behavior toward the pre-stress state.

Selank’s gentle reputation has less pull on me after that experiment. A compound can look relatively gentle in one setting and still alter the effect of another drug. Human combination safety remains unresolved. The Selank research page starts with this interaction, then turns to the small anxiety trial, immune findings and amidate questions.

Semax across brain regions

In male rats given Semax, BDNF and NGF gene expression rose in the hippocampus, BDNF rose in the brainstem and cerebellum, while NGF mRNA fell in the frontal cortex. These growth-supporting proteins are often compressed into an appealing story about more brain growth factors. For all the talk of boosting brain growth factors, I prefer the Semax pattern in full, including its decrease.

That falling NGF result sent me back through the rest of the paper’s findings. Semax’s regional effects lead into research on injured tissue, where the question is recovery rather than everyday concentration. The comparison puts the actual experiments alongside one another.

When someone reports nothing

Community accounts of all three peptides include people who felt little or nothing, alongside accounts of calm, clearer thinking or better sleep. Those are anecdotal accounts, not clinical evidence. They cannot tell us the proportion of people who benefit or identify the cause of an unwanted effect.

I believe the DSIP disappointments deserve as much time as the theories invented to explain them away. With DSIP especially, the review of its unresolved biology gives ample reason to tolerate an unfinished answer: the authors found weakly documented sleep effects and no identified receptor, gene or precursor. Curiosity can survive that. Certainty will have to wait.